Gene Therapy Study for Children With CLN5 Batten Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-31

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, non-randomized, open-label, dose escalation study of a single administration of gene therapy in children who are 3 to 9 years old with Neuronal Ceroid Lipofuscinosis (Batten) Subtype 5 (CLN5) disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gene Therapy for Children With CLN3 Batten Disease

NCT03770572

CLN3 Batten Disease

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis

NCT00151216

Batten Disease Late Infantile Neuronal Ceroid Lipofuscinosis

COMPLETED PHASE1

Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease

NCT02725580

Variant Late-Infantile Neuronal Ceroid Lipofuscinosis

COMPLETED PHASE1/PHASE2

Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)

NCT01161576

Batten Disease Late-Infantile Neuronal Ceroid Lipofuscinosis

COMPLETED PHASE1

AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis

NCT01414985

Late Infantile Neuronal Ceroid Lipofuscinosis Batten Disease

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a first in human (FIH) open-label, dose escalation study designed to assess the safety and efficacy of administration of an adeno-associated viral vector serotype 9 (AAV9) carrying the gene encoding human ceroid-lipofuscinosis neuronal protein 5 (CLN5) in subjects with CLN5 Batten disease. The study treatment will be delivered via intracerebroventricular (ICV) and intravitreal (IVT) injection on the same day. Each participant will be followed for safety and efficacy for 5 years after treatment. Efficacy assessments in this study will evaluate motor, language, visual and cognitive function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuronal Ceroid Lipofuscinosis CLN5

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Dose escalation cohort study of NGN-101 administered by intracerebroventricular (ICV) infusion and intravitreal (IVT) injection; cohorts will be assigned sequentially.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

The study treatment is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).

Group Type EXPERIMENTAL

NGN-101

Intervention Type GENETIC

Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.

Cohort 2

The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon-optimized human CLN5 transgene (hCLN5opt).

Group Type EXPERIMENTAL

NGN-101

Intervention Type GENETIC

Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.

Cohort 3

The study treatment is a higher dose of recombinant serotype 9 adeno-associated virus encoding a codon- optimized human CLN5 transgene (hCLN5opt).

Group Type EXPERIMENTAL

NGN-101

Intervention Type GENETIC

Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NGN-101

Participants with confirmed mutations in the CLN5 gene who meet all the inclusion and none of the exclusion criteria will be treated with a single intracerebroventricular (ICV) dose and a single intravitreal (IVT) dose of the study treatment.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 3 to 9 years (Child)
* Molecular genetic diagnosis of the CLN5 gene
* Confirmed clinical diagnosis of CLN5 disease
* Impaired motor and/or language function and/or impaired visual acuity
* Written informed consent from parent or legal guardian and assent from study participant, if appropriate
* Able to comply with protocol required assessments (laboratory sample collection, lumbar puncture (LP), nerve conduction studies (NCS), magnetic resonance imaging (MRI), etc.), which may require sedation or general anesthesia
* Able to walk with or without assistance (assistance may include a walker, braces, or with one hand held)
* Agree to reside within a 1-hour drive of the study site for at least 6 months following treatment (or a safely drivable distance for the study participant and caregivers according to investigator's discretion)

Exclusion Criteria

* Has another neurologic disease or illness that may have caused cognitive decline before study entry
* Known pathogenic or clinically suspected variant in a seizure associated genetic mutation besides CLN5
* Any active infections or severe infections within the 30 days prior to study treatment administration
* Presence of a concomitant medical condition that precludes intracerebroventricular (ICV) injection, lumbar puncture (LP), or use of anesthetics needed for study-related procedures
* Presence of any concomitant medical conditions that preclude intravitreal (IVT) administration
* Has status epilepticus that lasts longer than 5 minutes or having more than 1 seizure within a 5-minute period, without returning to a normal level of consciousness between episodes within 12 weeks before study treatment
* Total anti-AAV9 antibody titer greater than 1:400
* Any anticipated need for major surgery in the next 24 months
* Participation in an Investigational New Drug, Investigational Device Exemption, or equivalent clinical study in the past 6 months
* Any prior participation in a study in which a gene therapy vector or stem cell transplantation was administered
* Participation in other investigational studies and non-interventional studies that have similar study assessments as this protocol while the study participant is enrolled in this study with the exception of sister studies sponsored by Neurogene
* History of or current chemotherapy, radiotherapy, or other immunosuppressive therapy within the past 3 months
* Use of prohibited medications
* Immunizations of any kind in the 45 days prior to study treatment
* Requiring daytime or nighttime ventilatory support at the time of Screening
* Any item which would exclude the study participant from being able to undergo brain magnetic resonance imaging (MRI) according to local institutional policy
* Known allergies or hypersensitivities to the required immunosuppression regime

Minimum Eligible Age

3 Years

Maximum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No